Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK/mTOR Signaling Pathway
Zhanlin Liao,Liangzhi Huang,Jun Chen,Ting Chen,Dezhi Kong,Qifeng Wei,Qiao Chen,Bin Deng,Yanyan Li,Shuai Zhong,Zugui Huang
DOI: https://doi.org/10.2147/dmso.s447182
2024-02-06
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Zhanlin Liao, 1, &ast Liangzhi Huang, 1, &ast Jun Chen, 2 Ting Chen, 1 Dezhi Kong, 1 Qifeng Wei, 1 Qiao Chen, 1 Bin Deng, 1 Yanyan Li, 1 Shuai Zhong, 1 Zugui Huang 1 1 Department of Endocrine, Affiliated Nanping First Hospital of Fujian Medical University, Nanping, Fujian, 353006, People's Republic of China; 2 Department of Ophthalmology, Affiliated Nanping First Hospital of Fujian Medical University, Nanping, Fujian, 353006, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zugui Huang, Department of Endocrine, Affiliated Nanping First Hospital of Fujian Medical University, No. 317 Zhongshan Road, Nanping, Fujian, 353006, People's Republic of China, Email Background: Type 2 diabetes (T2DM) combined nonalcoholic fatty liver disease (NAFLD) are characterized by metabolic disruptions. Liraglutide has been proved to be effective in T2DM. If LRG could regulate NAFLD combined T2DM has not been reported. Methods: Intraperitoneal injection of 1% streptozotocin (STZ) plus high-sugar and high-fat diet was used to induce NAFLD combined T2DM animal model. Palmitic acid (200 μmol/L) and glucose (25 mmol/L) incubation were used to induce cell model. The cell apoptosis, mRNA and protein expression were measured through flow cytometry, PCR, and Western blotting, respectively. Results: Liraglutide significantly improved the liver injury of NAFLD combined T2DM rats, but Com-C reversed the effect of liraglutide. The decreased AMPK/mTOR signaling pathway in the NAFLD combined T2DM animals was greatly activated by liraglutide. Com-C reversed the protection effects of liraglutide on palmitic acid+glucose induced cell damage. Conclusion: Liraglutide could greatly alleviate the damage caused by NAFLD+T2DM and palmitic acid+glucose. The protection effects of liraglutide were greatly inhibited by suppressing AMPK/mTOR signaling pathway. This research might provide a novel therapeutic strategy for the prevention and treatment of NAFLD combined T2DM disease. Keywords: type 2 diabetes, nonalcoholic fatty liver disease, liraglutide, AMPK/mTOR, autophagy Type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD) are common chronic diseases characterized by metabolic disruptions, and their mutual influence can lead to adverse consequences. 1 Epidemiological studies conducted abroad have also shown a close relationship between diabetes and NAFLD, with a significantly higher prevalence of NAFLD in individuals with abnormal glucose metabolism compared to those with normal glucose metabolism. 2,3 In 2017, the International Diabetes Federation (IDF) reported that there are approximately 425 million adults worldwide living with diabetes, with China having an alarmingly high number of 114 million diabetic patients, among whom the prevalence of comorbid nonalcoholic fatty liver disease ranges from 28% to 70%. 4 Therefore, research on the co-occurrence of T2DM and NAFLD is of paramount importance. Adenosine monophosphate-activated protein kinase (AMPK) and mammalian target of rapamycin complex 1 (mTORC1) are two central kinase complexes responsible for sensing intracellular nutrient levels, regulating metabolic balance, and controlling cell growth. 5 AMPK plays a crucial role in maintaining cellular energy homeostasis and is a major regulator of both lipid and glucose metabolism. 6 It is closely associated with various metabolic disorders such as obesity and diabetes. AMPK is activated by sensing changes in the ratio of ATP to AMP. 7 It detects states of lower nutrient and energy levels and becomes activated under these conditions. AMPK inhibits synthetic metabolic pathways to reduce ATP consumption, promotes catabolic pathways to increase ATP production, and inhibits cell growth to ultimately ensure energy homeostasis. 8 mTORC1 is a protein kinase complex that is activated at the surface of lysosomes. It promotes cell growth and proliferation by enhancing protein translation and synthesis, inhibiting autophagy, and promoting the synthesis of fatty acids and nucleotides. 9 Therefore, mTORC1 activation requires the simultaneous presence of growth factors, glucose, amino acids, sufficient oxygen, and high energy levels within the cell. It has been confirmed that the relative activities of mTORC1 and AMPK under different cellular conditions largely determine the extent of autophagy induction. 10 Several studies have shown a protective role of the AMPK/mTORC1 autophagy signaling pathway in conditions such as neuronal damage and myocardial hypertrophy. -Abstract Truncated-
endocrinology & metabolism